METABOLIC DISEASES EXPERTS

Physiogenex is directed by highly skilled metabolic disease experts with a high level of experience in the field of drug discovery and preclinical development. The Management team is supported by dedicated collaborators working towards innovation, client satisfaction and quality compliance.

PHYSIOGENEX’S DIRECTORS

Thierry Sulpice, Ph.D

Thierry Sulpice, Ph.D

CEO, CSO, Founder, Member of the Scientific Advisory Board.

From 1995 to 2003, Thierry was Research Scientist then head of the Cardiovascular and Metabolic Diseases Unit, working on new cardiometabolic targets at Sanofi-Aventis. He founded Physiogenex in 2003 and is now CEO/CSO of the company.

During his 9-year tenure at Sanofi-Aventis, Thierry was in charge of drug discovery optimization and preclinical development for projects targeting the cardiometabolic syndrome. He was particularly involved in the cannabinoid FCB1 receptor program. He managed many in vivo studies which aimed to determine the potential efficacy of new drug targets. He developed several in vivo technologies and new models which directly reproduced metabolic disorders and heart diseases.

His expertise also covers the physiopathology and pharmacology of type 2 diabetes, dyslipidaemia, vascular/heart diseases, liver and kidneys disorders. Thierry holds a PhD in Physiology and Pharmacology from the University of Grenoble, France. Since 1990 he has been actively engaged in basic research on cardiovascular physiopathology and spent one year working on the physiopathology of the diabetic heart at Orsay University, France.

In addition, he is the founder and CEO/CSO of Cardiomedex, a preclinical CRO dedicated to cardiovascular disorders, onco-cardiology and neurocardiology.

François Briand, Ph.D

François Briand, Ph.D

Director of Research and Business Development, Member of the Scientific Advisory Board.

François has served as an expert in metabolic diseases since 2007. He has worked extensively on the development of novel in vivo assays and animal models of obesity/type 2 diabetes and related co-morbidities, all presented in international meetings and published in numerous scientific journals.

In 2016, François received the ASBMB Journal of Lipid Research Junior Investigator Award, as well as the Berman-Zech Award in 2018, for his research work on preclinical evaluation of drugs targeting type 2 diabetes, dyslipidaemia, diabetic nephropathy and NASH.

In 2006, he worked in the laboratory of Pr. Daniel J. Rader in Philadelphia, USA. In collaboration with pharmaceutical companies, his work focused on novel drugs affecting lipoprotein metabolism and reverse cholesterol transport in various mouse models.

François earned his Ph.D. in Nutrition and Metabolism from the University of Nantes, France. It dealt with the development of a canine model of obesity and insulin resistance, for evaluating drugs targeting type 2 diabetes and diabetic dyslipidaemia.

MANAGEMENT

Emmanuel Brousseau

Emmanuel Brousseau

Project Engineer, Laboratory Manager

Emmanuel obtained a University Degree in Life Sciences at the “Université de Nantes”, followed by a Technical Degree in biological and biochemical analysis at the “Université d’Auvergne”. In 1997, he joined Cephalon France, a biotechnology and pharmaceutical company where he worked for 8 years as a senior technician. His work focused on both cardiovascular and central nervous system areas on in vivo models.

In 2006, Emmanuel joined Physiogenex as a senior technician. Over the years, he developed his technical expertise on models and studies for metabolic disorders and became Engineer Assistant, Project Engineer and Laboratory Manager. Today, Emmanuel manages, on a day-to-day basis, the team of technicians and he coordinates schedules and laboratory operations. He also operates in R&D projects and client studies. His technical expertise is required to evaluate the feasibility and implementation of studies.

Marjolaine Quinsat

Marjolaine Quinsat

Assistant Engineer, Zootechnics Division Manager

Marjolaine holds a Biological and Biochemical technical degree and a Biotechnology Bachelor’s Degree from the “Université Blaise Pascal de Clermont-Ferrand”. She first joined the Baugy Biological Research Centre, where she was a pharmacology and toxicology lab technician. She worked for 6 years on various in vivo models to test drugs in preclinical phase for a broad range of targets.

In 2013, Marjolaine joined Physiogenex as a senior laboratory technician. Her missions were to schedule the studies, organize results delivery and statistics. Since 2019, Marjolaine is Assistant Engineer and Zootechnics Division Manager. She currently manages the team of zootechnicians and oversees the organization of schedules and project management for customer studies and R&D.

Sura Setau

Sura Setau

QHSE Manager

Sura holds a Master’s degree in quality, Security and Environment Management. Prior to joining Physiogenex, she worked as a Coordinator of Quality, Security and Environment management at Sogeti France, an IT consulting company. She prepared ISO 14001 certification renewal, regulatory monitoring for quality certifications, and databases for risk management. In 2016, Sura joined Physiogenex as QSE manager. Besides laboratories and facility security, and environment management, she ensures that our Quality Management System complies with customers, internal, ISO 9001 and regulatory requirements.

Julie Arasse

Julie Arasse

Administrative and Financial manager

Julie obtained her diploma of Accounting and Company Management in 2007. She worked as an accountant for various companies before joining Physiogenex in 2011 as Social and Accounting Affairs Officer. Since 2018, she is our Administrative and Financial Manager. She handles human resources, accounting, finances and the overall administrative management of Physiogenex.

CHAIRMAN OF THE SCIENTIFIC ADVISORY BOARD

Pr. Remy Burcelin, Ph.D.

Pr. Remy Burcelin, Ph.D.

Chairman of the Scientific Advisory Board and Founder

Pr. Burcelin is a Research Director at the French National Medical Research Institute (INSERM, Inserm/UPS I2MC 1048), since 2008. Pr. Burcelin is an internationally renowned specialist on molecular bases of glycaemic control, notably insulin resistance and the role of the intestine (microbiota & glucoincretins (GLP-1 and GIP) on the gut brain axis, thereby studying metabolic and cardiovascular diseases). He founded the EASD Incretin Study Group of which he is the Chairman. Pr Burcelin has published more than 120 peer reviewed publications in international journals and has founded and contributed to 7 biotech companies.

From 2001 to 2007, he headed a research team at the National Centre for Scientific Research (CNRS). From 1995 to 2000, he was Assistant Professor at the Institute of Pharmacology and Toxicology in a research laboratory headed by Pr. B. Thorens in Lausanne, Switzerland. Pr. Burcelin gained his PhD in molecular endocrinology in 1992 and completed his studies at the Jacques Monod Institute (Paris, France) and the Albert Einstein College of Medicine (Pr.  M.J. Charron, New York, USA) until 1995.

Pr. Burcelin is a reviewer for major journals in biological science, notably diabetes, obesity, cardiovascular diseases, microbiology, and an advisor to many international pharmaceutical, agro-food and biotechnology companies. He is also a member of several international societies, such as the French Society for Diabetes (SFD), the European Foundation for the Study of Diabetes (EFSD) and the American Diabetes Association (ADA).

CONTACT US FOR MORE INFORMATION